JYAMS PET Research and Development

JYAMS PET Research and Development (also known as Nanjing Jiangyuan Andik Positron Research and Development) is a Chinese radiopharmaceutical company specializing in the development, manufacture, and distribution of positron emission tomography (PET) diagnostic tracers. Operating as a wholly-owned subsidiary of Yantai Dongcheng Pharmaceutical Group, the company has established a comprehensive network of nuclear medicine production centers across China. Its pipeline features advanced diagnostic imaging agents, including the tau-targeting PET tracer [18F]Florzolotau (APN-1607) in Phase 3 development for Alzheimer's disease, and the newly approved Sodium Fluoride [18F] Injection for bone imaging. Through its extensive network, JYAMS PET provides critical diagnostic solutions for oncology, neurology, and cardiology, supporting the growing demand for precision medicine and molecular imaging in China.